CAL
VRTX icon

Capital Advisors Ltd’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Advisors Ltd’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Buy
99
+30
+43% +$13.3K ﹤0.01% 516
2026
Q1 		$31K Sell
69
-8
-10% -$3.73K ﹤0.01% 596
2025
Q4 		$35K Buy
77
+27
+54% +$11.6K ﹤0.01% 563
2025
Q3 		$20K Buy
50
+2
+4% +$836 ﹤0.01% 650
2025
Q2 		$21K Hold
48
– – ﹤0.01% 619
2025
Q1 		$23K Buy
48
+17
+55% +$7.92K ﹤0.01% 596
2024
Q4 		$12K Sell
31
-3
-9% -$1.39K ﹤0.01% 749
2024
Q3 		$16K Hold
34
– – ﹤0.01% 662
2024
Q2 		$16K Sell
34
-2
-6% -$868 ﹤0.01% 639
2024
Q1 		$15K Buy
36
+6
+20% +$2.54K ﹤0.01% 645
2023
Q4 		$12K Hold
30
– – ﹤0.01% 670
2023
Q3 		$10K Sell
30
-1
-3% -$350 ﹤0.01% 692
2023
Q2 		$11K Hold
31
– – ﹤0.01% 688
2023
Q1 		$10K Buy
31
+9
+41% +$2.7K ﹤0.01% 567
2022
Q4 		$6K Hold
22
– – ﹤0.01% 639
2022
Q3 		$6K Hold
22
– – ﹤0.01% 613
2022
Q2 		$6K Buy
22
+13
+144% +$3.48K ﹤0.01% 561
2022
Q1 		$2K Buy
9
+6
+200% +$1.42K ﹤0.01% 657
2021
Q4 		$1K Buy
+3
New +$583 ﹤0.01% 761

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Capital Advisors Ltd's VRTX Position: Q2 2026 in Review

Capital Advisors Ltd increased its Vertex Pharmaceuticals (VRTX) stake by 43% in Q2 2026, buying an estimated $13.3K and bringing the position to 99 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #516.

Capital Advisors Ltd first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. 303 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital Advisors Ltd held 99 shares of Vertex Pharmaceuticals worth $49K as of Q2 2026.
  • Capital Advisors Ltd bought 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #516 holding.
  • Capital Advisors Ltd first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 303 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.